. . . . . . . . . . . . . . . . "ensayu cl\u00EDnicu"@ast . . . . . . . "955"^^ . . . . . . . . . . . . . . . . . . . . . "2013-07-08T00:00:00Z"^^ . "18"^^ . . . . . . . . . . . . . . . "CLARION"@en . . . . "Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma"@en . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . . . . . "Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma"@en . . . . . . . . . . . . . . . . . . . . . "klinisch onderzoek"@nl . "Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma"@en . . . . . . . . . . . "2016-07-15T00:00:00Z"^^ . . . . "A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma"@en . . . . "NCT01818752" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "clinical trial"@en . . . . . . . . . . . . . . . . . . . .